康华生物 reported revenue of ¥0.54B for the period ended 2026-06-30, +11.2% year on year. Net income was ¥0.14B, a 26.2% net margin on a 89.8% gross margin. The largest revenue line is 非免疫规划疫苗 at 100% of the total. Free cash flow for the period was ¥0.14B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.54B | +11.2% |
| Gross profit | ¥0.48B | — |
| Operating income | ¥0.16B | — |
| Net income | ¥0.14B | +23.3% |
| Gross margin | 89.8% | Net margin 26.2% |
| Revenue Q/Q | +112.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 非免疫规划疫苗 | ¥0.54B | 100.0% |
| 其他(补充) | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.06B | 10.2% |
| R&D | ¥0.04B | 7.5% |
| SG&A | ¥0.27B | 50.4% |
| Tax & other | ¥0.02B | 3.3% |
| Item | Amount |
|---|---|
| Total assets | ¥3.97B |
| Total liabilities | ¥0.36B |
| Shareholders' equity | ¥3.61B |
| Equity / assets | 91.0% |
| Operating cash flow | ¥0.14B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.14B |
| Cash conversion (OCF / net income) | 114% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
帝科股份 ・ 胜蓝股份 ・ 山水比德 ・ 捷安高科 ・ 首都在线 ・ 中船汉光 ・ 美瑞新材 ・ 锦盛新材 ・ 新强联 ・ 交大思诺 ・ 四会富仕 ・ 申昊科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies